Pablo Jiménez· @PaulJiL · X·· 1 day agoScore45
Body
#ESMO26 #HNSCC
Nice presentation from Dr Even about the systemic approach of HPV+ HNSCC
My take: Is time to end with antiEGFR agents in HPV+ HNSCC? or shall we keep it as a last resource in latter lines
None of the major guidelines (ASCO, ESMO and NCCN) do make any clear recommendation against/disadvice
@OncoAlert @myESMO @brunolarvol
@DavidSherMD
54 views · 3 likes · 3 reposts · 0 replies
Conference abstracts
NCT06295731NCT06295731matched by - **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
https://esmocongress.esmo.orgSource: Pablo Jiménez · x.com